Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …

An estimated 24 million people worldwide have dementia, the majority of whom are thought
to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health …

In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …

Objective: To test blood and CSF neurofilament light chain (NfL) levels in relation to disease
progression and survival in amyotrophic lateral sclerosis (ALS). Methods: Using an …

Imaging has played a variety of roles in the study of Alzheimer disease (AD) over the past
four decades. Initially, computed tomography (CT) and then magnetic resonance imaging …

Objective: To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for
diagnosing early-stage Alzheimer disease (AD). Methods: From the prospective, longitudinal …

Importance Before adding cerebrospinal fluid (CSF) biomarkers to the diagnostic workup of
Alzheimer disease, it needs to be determined whether CSF biomarkers analyzed in routine …

Large phenotypically diverse research cohorts with both amyloid and tau PET have only
recently come into existence. Our objective was to determine relationships between the …

Gray matter atrophy, glucose hypometabolism, and β-amyloid Aβ deposition are well-
described hallmarks of Alzheimer's disease, but their relationships are poorly understood …

Objective We examined agreement and disagreement between 2 biomarkers of β‐amyloid
(Aβ) deposition (amyloid positron emission tomography [PET] and cerebrospinal fluid [CSF] …